Literature DB >> 14994846

Pharmacological rate control of atrial fibrillation.

Leonardo J Tamariz1, Eric B Bass.   

Abstract

To control ventricular rate in patients with AF, physicians should seek to control heart rate at rest and with exertion. The goal has to be achieved while minimizing costs and adverse effects. For emergency use, i.v. diltiazem or esmolol are drugs useful because of their rapid onset of action. They have to be used with caution in patients with concomitant left ventricular failure symptoms, however. For most patients with AF, chronic control of the ventricular rate can be achieved with one drug. For the chronic control of ventricular rate in patients with AF and normal ventricular function, diltiazem, atenolol, are metoprolol are probably the drugs of choice. For patients with AF and structurally abnormal hearts, atenolol, metoprolol, or carvedilol are appropriate choices. Adequate ventricular rate control by pharmacological agents should be evaluated by either 24-hour Holter monitoring or a submaximal stress test to determine the resting and exercise ventricular rate. If the mean ventricular rate is not close to 80 beats per minute, or the heart rate on moderate exertion is not between 90 to 115 beats per minute, a second agent to control the rate should be added. Excessive reductions in ventricular rates that could limit exercise tolerance should be avoided.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14994846     DOI: 10.1016/s0733-8651(03)00111-5

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  8 in total

Review 1.  Computational approaches to structural and functional analysis of plastocyanin and other blue copper proteins.

Authors:  F De Rienzo; R R Gabdoulline; R C Wade; M Sola; M C Menziani
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

2.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

3.  A practical approach to the management of patients with atrial fibrillation.

Authors:  Christopher J McLeod; Bernard J Gersh
Journal:  Heart Asia       Date:  2010-09-06

4.  A comparison of verapamil and digoxin for heart rate control in atrial fibrillation.

Authors:  Mohammad Afzali Moghadam; Maryam Fadaie Dashti; Kavous Shahsavarinia; Ata Mahmoodpoor; Kazem Jamali
Journal:  Adv Pharm Bull       Date:  2012-08-15

5.  Present concepts in management of atrial fibrillation: From drug therapy to ablation.

Authors:  Giovanni B Forleo; Luca Santini; Francesco Romeo
Journal:  World J Cardiol       Date:  2009-12-31

6.  Structural Basis for Diltiazem Block of a Voltage-Gated Ca2+ Channel.

Authors:  Lin Tang; Tamer M Gamal El-Din; Michael J Lenaeus; Ning Zheng; William A Catterall
Journal:  Mol Pharmacol       Date:  2019-08-07       Impact factor: 4.436

7.  Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study.

Authors:  James V Freeman; Kristi Reynolds; Margaret Fang; Natalia Udaltsova; Anthony Steimle; Niela K Pomernacki; Leila H Borowsky; Teresa N Harrison; Daniel E Singer; Alan S Go
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-11-20

Review 8.  [Rate versus rhythm control with and without heart failure].

Authors:  Florian Straube; Uwe Dorwarth; Sabine Janko; Ellen Hoffmann
Journal:  Herz       Date:  2008-12       Impact factor: 1.443

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.